METROPOLIS

- Consolidated revenue grew ~15% YoY driven by double-digit patient and test volume growth and improved realizations. - TruHealth Wellness and Specialty segments emerged as fastest-growing. - EBITDA margins improved meaningfully on both YoY and QoQ basis due to operating leverage and efficiency gains.

- Trading window closed with effect from September 29, 2026. - Closure remains effective until 48 hours after declaration of financial results for quarter and half year ending September 30, 2026. - Date of the Board Meeting will be intimated in due course.

- Metropolis Healthcare Ltd. allotted 66,312 equity shares to employees under the Metropolis-Restrictive Stock Unit Plan, 2020 on September 09, 2026. - The shares were allotted at an exercise price of INR 2/- each, aggregating to ₹1,32,624. - 50% of the allotted shares are subject to a 1-year lock-in period from the date of allotment.

- Metropolis Healthcare's subsidiary Metropolis Quality Solutions Private Limited (MQSPL) entered into a Share Subscription Agreement and Shareholder's Agreement with Medsource Ozone Biomedicals Private Limited and Dr. Puneet Kumar Nigam on September 07, 2026. - The restructuring aims to consolidate and streamline MQSPL's External Quality Assessment Services Business. - Medsource will invest approximately ₹1.10 crore and Dr. Puneet Kumar Nigam ₹16 lakh in MQSPL. - Upon full dilution, MQSPL's shareholding will be MHL (54.90%), Medsource (30.60%), and Dr. Puneet (14.50%).

- FY26 Consolidated Revenue was ₹1,646 Cr with an EBITDA Margin of 24.4% (organic 25.9%). - Achieved 17.6% revenue CAGR and 18.6% EBITDA CAGR over the last 3 years; Q1 growth was 17%. - Management guides for 14-15% revenue growth for the next 3-4 quarters, without price increases. - Targets to improve EBITDA margin from 24.4% to 27-28% in the next 2-3 years, driven by mix improvement towards specialty/genomics, productivity, and network utilization. - Plans to establish ~100 asset-light radiology mini hubs with an estimated capex of ₹35-40 lakhs per hub, anticipating a 2x-3x increase in productivity. - Specialty business, currently 40% of revenue, is targeted for disproportionate growth, with genomics showing 2x growth in the last year. - Digital initiatives contribute 25% of business, with ongoing integration of AI for report summarization, diet guidance, and customer service. - The company emphasizes volume-led growth, continuous reinvestment in technology and network expansion, and a long-term vision to be the number one diagnostics player in India.

- Audio recording of the Investors & Analyst Meet held on August 27, 2026, at 04:00 p.m. (IST) is available on Metropolis Healthcare Ltd.'s website.

- Metropolis Healthcare Ltd. transferred its External Quality Assessment Services (EQAS) Division to its subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), effective August 27, 2026. - The transfer was a slump sale for INR 1.25 crore, discharged via MQSPL equity shares.

- Metropolis Healthcare Limited released an Investor Presentation for an Investors & Analyst Meet scheduled for August 27, 2026, at 04:00 p.m. (IST). - For FY26, Revenue from Operations was ₹1,646 Cr, EBITDA ₹401 Cr, and PAT ₹191 Cr. - The company aims for mid-teen volume-led revenue growth over the next three years.

- Metropolis Quality Solutions Private Limited (MQSPL), a wholly-owned subsidiary of Metropolis Healthcare Limited, approved the issuance of Optionally Convertible Redeemable Preference Shares (OCRPS). - Upon successful subscription and conversion, MQSPL will cease to be a wholly-owned subsidiary but will continue to remain a subsidiary. - The OCRPS, aggregating to ₹1,00,000, will be issued to Dr. Puneet Kumar Nigam, a former Chief Quality Officer.

- Investor & Analyst Meet Schedule - Meeting Date: August 27, 2026 - Meeting Time: 04:00 p.m. (IST) onwards - Type of Interaction: Large format Investors & Analyst Group Meeting

New Filing detected. See link for details.

- Audio recording of the earnings conference call for Q1 FY27 (quarter ended June 30, 2026) is available on the company's website. - The conference call was held on August 05, 2026, at 09:00 a.m. (IST).

- Consolidated Revenue ₹450.2 Cr vs ₹386.1 Cr (▲16.6% YoY) - EBITDA ₹113.2 Cr vs ₹89.1 Cr (▲27.1% YoY) - PAT ₹56.9 Cr vs ₹45.2 Cr (▲25.8% YoY) - EBITDA Margin 25.2% vs 23.1% (▲210bps)

- Consolidated Revenue ₹4,502.15 million vs ₹3,860.63 million (▲17% YoY) - EBITDA ₹1,111.93 million vs ₹897.57 million (▲24% YoY) - PAT ₹568.83 million vs ₹452.45 million (▲26% YoY) - EBITDA Margin 24.69% vs 23.25% (▲144bps) - Board noted an additional 2 months needed to complete the sale and transfer of External Quality Assessment Services Business.